TY - JOUR

T1 - Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion

AU - Traustason, Sindri

AU - la Cour, Morten

AU - Larsen, Michael

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2014/9

Y1 - 2014/9

N2 - PURPOSE: To investigate the effect of intravitreal injections of the vascular endothelial growth factor inhibitor ranibizumab on retinal oxygenation in patients with central retinal vein occlusion (CRVO).METHODS: Retinal oxygen saturation in patients with CRVO was analysed using the Oxymap Retinal Oximeter P3, before and during 6 months of treatment with intravitreal injections of ranibizumab.RESULTS: At presentation, retinal venous oxygen saturation was lower in eyes with CRVO than in the healthy fellow eyes (32±13% vs 59±10%, respectively, p=0.001) whereas retinal arterial saturation was higher in eyes with CRVO than in the fellow eyes (95%±8% and 91%±3%, p=0.04). Mean visual acuity increased from 51±24 letters ETDRS at baseline to 66±24 and 69±20 letters ETRDS, respectively, at 3 months and 6 months treatment (mean±SD, p<0.0001, repeated measures analysis of variance) and central retinal thickness was reduced from 697±139 µm to 368±113 µm and 340±96 µm, respectively, from baseline to 3 months and 6 months treatment (p<0.0001). Venous saturation increased during treatment (from 35.5%±13.8% at baseline to 43.1%±10.8% and 43.5%±13.7% after 3 months and 6 months treatment, respectively, p=0.012), while no significant change was found in arterial saturation (p=0.24).CONCLUSIONS: Retinal venous oxygen saturation was markedly reduced in untreated CRVO and was roughly halfway normalised during intravitreal ranibizumab treatment. Retinal artery oxygen saturation was not reduced in CRVO.TRIAL REGISTRATION NUMBER: NCT01360385.

AB - PURPOSE: To investigate the effect of intravitreal injections of the vascular endothelial growth factor inhibitor ranibizumab on retinal oxygenation in patients with central retinal vein occlusion (CRVO).METHODS: Retinal oxygen saturation in patients with CRVO was analysed using the Oxymap Retinal Oximeter P3, before and during 6 months of treatment with intravitreal injections of ranibizumab.RESULTS: At presentation, retinal venous oxygen saturation was lower in eyes with CRVO than in the healthy fellow eyes (32±13% vs 59±10%, respectively, p=0.001) whereas retinal arterial saturation was higher in eyes with CRVO than in the fellow eyes (95%±8% and 91%±3%, p=0.04). Mean visual acuity increased from 51±24 letters ETDRS at baseline to 66±24 and 69±20 letters ETRDS, respectively, at 3 months and 6 months treatment (mean±SD, p<0.0001, repeated measures analysis of variance) and central retinal thickness was reduced from 697±139 µm to 368±113 µm and 340±96 µm, respectively, from baseline to 3 months and 6 months treatment (p<0.0001). Venous saturation increased during treatment (from 35.5%±13.8% at baseline to 43.1%±10.8% and 43.5%±13.7% after 3 months and 6 months treatment, respectively, p=0.012), while no significant change was found in arterial saturation (p=0.24).CONCLUSIONS: Retinal venous oxygen saturation was markedly reduced in untreated CRVO and was roughly halfway normalised during intravitreal ranibizumab treatment. Retinal artery oxygen saturation was not reduced in CRVO.TRIAL REGISTRATION NUMBER: NCT01360385.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors

KW - Antibodies, Monoclonal, Humanized

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Intravitreal Injections

KW - Male

KW - Middle Aged

KW - Oximetry

KW - Oxygen

KW - Prospective Studies

KW - Retinal Artery

KW - Retinal Vein

KW - Retinal Vein Occlusion

KW - Tomography, Optical Coherence

KW - Vascular Endothelial Growth Factor A

KW - Visual Acuity

U2 - 10.1136/bjophthalmol-2013-304580

DO - 10.1136/bjophthalmol-2013-304580

M3 - Journal article

C2 - 24729079

VL - 98

SP - 1208

EP - 1211

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 9

ER -